Markers of Cell Death and Cancer Outcomes
Author Information
Author(s): Paradiso A, Simone G, Lena M De, Leone B, Vallejo C, Lacava J, Dellapasqua S, Daidone M G, Costa A
Primary Institution: Clinical Experimental Oncology Laboratory, National Oncology Institute, Bari, Italy
Hypothesis
The study investigates the clinical relevance of bax and bcl-2 protein expression in patients with advanced colorectal cancer undergoing chemotherapy.
Conclusion
The study found no clear association between apoptosis-related markers and clinical outcomes in advanced colorectal cancer patients.
Supporting Evidence
- Cytoplasmic immunostaining of bax and bcl-2 was present in 65.5% and 38% of the tumors, respectively.
- No association was found between bax and bcl-2 or between p53 and bax or bcl-2 protein expression.
- Bcl-2-negative lesions were more frequent among patients who reached an objective clinical response.
- A better response rate (40%) was found for patients whose tumors did not express p53 and bax.
Takeaway
The study looked at how certain proteins related to cell death affect cancer treatment results, but they didn't find a strong link.
Methodology
Patients were treated with a chemotherapy regimen including methotrexate and fluorouracil/leucovorin, and protein expression was assessed through cytoplasmic immunostaining.
Limitations
The biomarkers were unrelated to patient and tumor characteristics known to affect clinical outcomes.
Participant Demographics
Patients with recurrent or metastatic colorectal cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website